内部人交易记录
董事尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the full record of transactions filed by Ganzi Victor F, 董事. Director active across 4 companies, notably Willis Towers Watson PLC. In total, 16 disclosures have been recorded. Split: 2 buys · 0 sell. Total volume traded: €2k. History available since 11 May 2021. The latest transaction was disclosed on 14 February 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Ganzi Victor F
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报16 总计
18,916 股0Common Stock, par value $0.01 per shareSEC:0001193125-26-055168:0
28,261 股0Common Stock, par value $0.01 per shareSEC:0000950170-25-032990:0
53,942 股0Common Stock, par value $0.01 per shareSEC:0000950170-24-019667:0
103,175 股Common StockSEC:0000950170-24-017527:0
61,611 股Common StockSEC:0000950170-23-044445:0
200 股@ US$1.2310.9% 占其流量Common Stock, par value $0.01 per shareSEC:0000899243-23-015025:0
1,758 股@ US$1.14289.1% 占其流量Common Stock, par value $0.01 per shareSEC:0000899243-23-014279:0
10,509 股Common StockSEC:0000899243-22-025153:0
128 股@ US$209.840.0001% mcap3.9% 占其流量Ordinary Shares, nominal value $0.000304635 per shareSEC:0001127602-22-017221:0
614,310 股@ US$6.43100.0% 占其流量Common StockSEC:0001601485-22-000044:0
791 股@ US$206.350.0007% mcap24.4% 占其流量Ordinary Shares, nominal value $0.000304635 per shareSEC:0001127602-22-014390:0
265 股0Ordinary Shares, nominal value $0.000304635 per shareSEC:0001127602-22-000931:0
1,049 股@ US$264.2555.9% 占其流量Ordinary Shares, nominal value $0.000304635 per shareSEC:0001127602-21-016540:0
122.97 股Class A Common StockSEC:0001127602-16-036373:0
14,827.21 股Class A Common StockSEC:0001127602-16-036373:1
14,827 股Ordinary Shares, nominal value $0.000304635 per shareSEC:0001127602-16-036427:0
About Ganzi Victor F
GANZI VICTOR F is Administrateur. He has 16 filings in total. In the 16 most recent filings we hold, buys amount to EUR 2100 and sells to EUR 0, over the period from 2016-01-06 to 2026-02-17, with filings linked to Aveanna Healthcare Holdings, Inc., Willis Towers Watson PLC, Towers Watson & Co. and Angion Biomedica Corp.